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AbstrAct
The cellular stress response autophagy has been implicated in various diseases 
including neuro-degeneration and cancer. The role of autophagy in cancer is not clearly 
understood and both tumour promoting and tumour suppressive effects of autophagy 
have been reported, which complicates the design of therapeutic strategies based 
on targeting the autophagy pathway. Here, we have systematically analyzed gene 
expression data for 47 autophagy genes for deletions, amplifications and mutations 
in various cancers. We found that several cancer types have frequent autophagy gene 
amplifications, whereas deletions are more frequent in prostate adenocarcinomas. 
Other cancer types such as glioblastoma and thyroid carcinoma show very few 
alterations in any of the 47 autophagy genes. Overall, individual autophagy core 
genes are altered at low frequency in cancer, suggesting that cancer cells require 
functional autophagy. Some autophagy genes show frequent single base mutations, 
such as members of the ULK family of protein kinases. Furthermore, we found hotspot 
mutations in the arginine-rich stretch in MAP1LC3A resulting in reduced cleavage of 
MAP1LC3A by ATG4B both in vitro and in vivo, suggesting a functional implication of 
this gene mutation in cancer development. 
INtrODUctION
Autophagy is a highly conserved process that 
serves two main functions in the cell: to provide energy 
under conditions of limited nutrient availability and to 
remove damaged organelles such as misfolded protein 
aggregates or non-functional mitochondria from the cell. 
As a consequence, malfunction of this process has severe 
consequences that contribute to various diseases including 
pathogen infection, neuro-degenerative disorders and 
cancer [1]. In addition, studies suggest that autophagy is 
contributing to the ageing process of an organism [2], a 
feature that may be linked to increased cancer occurrence 
in aged cells. It has been suggested that autophagy plays 
a key role in the initiation, progression and differentiation 
of tumours and to enhance tumour cell survival under 
conditions of cellular stress and has also been postulated 
to serve as a tumour suppressive mechanism [3, 4]. 
The most compelling evidence for autophagy as a 
tumour suppressive mechanism is based on the finding that 
Beclin-1 (BECN1), a gene involved in autophagosome 
formation, has been found haploinsufficient in around 50% 
of breast, ovarian and prostate cancers [5]. Furthermore, 
BECN1 hemizygous mice develop lymphoma, liver and 
lung cancers [6, 7]. However, a more detailed analysis 
of sequencing data has recently suggested that loss of 
the neighbouring gene, BRCA1, is the primary driver 
alteration in cancer [8]. In addition to BECN1, frameshift 
mutations in core autophagy genes ATG2B, ATG5, 
ATG9B and ATG12 in colorectal cancers have been 
reported, providing additional evidence for a tumour 
suppressive role [9]. Furthermore, mice lacking the 
ZBTB24 or ATG4C gene are prone to tumourigenesis 
[10, 11]. Mechanistically, the tumour suppressive role has 
been mainly attributed to an increase of reactive oxygen 
species and DNA damage when autophagy is impaired 
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[12], although other mechanisms may be relevant as well. 
On the other hand, autophagy can promote tumour 
growth by multiple mechanisms including the suppression 
of p53 activity, as well as maintaining mitochondrial 
function and enhancing survival under conditions of 
stress [13]. A seminal paper in 2006 described promotion 
of tumour necrosis when autophagy was inhibited in 
apoptosis-defective cells, thus leading to the concept of 
autophagic cell death under conditions of metabolic stress 
[14]. In addition, the deletion of RB1CC, an essential 
autophagy gene, inhibits oncogene-driven tumourigenesis 
[15]. Furthermore, it has been shown that ATG4B can 
promote growth of CML and colorectal cancer cells 
[16, 17]. Since cancer cells undergo periods of nutrient 
limitation, it has been proposed that autophagy benefits the 
tumour by promoting cell survival under stress conditions. 
Based on the crucial role of autophagy in 
tumourigenesis, treatments exploiting the autophagy 
pathway have been suggested. These recent clinical 
advances are supported by two prevailing hypotheses that 
are based on the important role of autophagy in stress-
induced cell death. One is that cancer cells undergo phases 
of cellular stress, leading to an upregulation of autophagy 
in general. Cellular stress can occur under conditions such 
as hypoxia, nutrient scarcity during tumour expansion or 
during treatment with chemotherapeutic agents. Under 
these conditions, a suppression of autophagy may result 
in stress-induced cell death and may be therapeutically 
exploited. On another account, autophagy displays 
a tumour suppressive role as has been suggested for 
Beclin-1 or ATG4C. In this instance hyper-stimulating 
autophagy may mimic a state of cellular stress leading to 
a ‘point of no return’ and consequently to “autophagic cell 
death”. So far, evidence for an induction of autophagic 
cell death specifically in tumour cells is lacking and this 
remains a hypothesis that needs to be proven. 
To date, close to 50 clinical trials have been 
reported to investigate the impact of autophagy inhibition 
using hydroxychloroquine or its derivatives, mTOR 
inhibitors or AKT inhibitors, usually in combination 
with chemotherapeutic agents (www.clinicaltrials.gov). 
Whether the effects of such treatments are indeed caused 
by modification of the autophagic pathway or alternative 
processes that are also targeted by such treatments is 
not clear, since robust autophagy assays essential for 
monitoring the in vivo effect of therapeutic agents on 
autophagy are missing. Until now, no clinical trial has 
reported to target the core autophagy machinery directly. 
In this study, we have undertaken an unbiased 
approach to evaluate expression of 47 key autophagy 
genes in a variety of human cancer samples. We find 
evidence that certain autophagy genes are prevalently 
altered over others and potential hotspot mutations 
are found in members of the ULK family of kinases, 
RB1CC1, PIK3C3 and VCP. We identified a frequent 
mutation of arginine 70 in MAP1LC3A that has led us to 
study the functional consequence of this mutation in more 
detail. We observed reduced LC3A processing and LC3A-
positive puncta formation as a consequence of the R70H 
mutation, suggesting a functional role. In summary, our 
study proposes that each individual tumour type displays 
a different autophagic signature that should be taken into 
account when designing therapeutic approaches.
rEsULts
Frequent autophagy gene amplifications in 
multiple cancers
In order to gain insight into the frequency of copy 
number alterations and mutational status of autophagy 
genes in tumour samples, we analyzed a set of 47 key 
autophagy genes (Supplementary Table 1) in the cBIO 
cancer genomics portal. These genes include components 
of the autophagy machinery and proteins involved 
in lysosomal function, but exclude general signaling 
Figure 1: Cumulative frequency of autophagy gene expression changes in various tumour types. 47 autophagy genes as 
listed in supplemental table 1 were investigated for copy number alterations in various cancer types that are included in the cBIO portal 
cancer sequencing database (www.cbioportal.org). Shown is the percentage of copy number alterations in each cancer sub-type. For a 
full list of abbreviations, please see Supplementary Table 1. Shown in blue colour are copy number deletions, in red are copy number 
amplifications and in green are mutations.
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molecules that have pleiotropic functions in mitogenic 
signaling (such as AKT or mTOR). Firstly, we assessed the 
cumulative frequency of copy number alterations for all 47 
genes in a variety of cancers (Figure 1). We found that at 
least one autophagy gene is altered frequently in multiple 
cancer types including Pancreatic Cancer (72.5%; 79 
cases), Ovarian Serous Cystadenocarcinoma (71.7%; 223 
cases), Bladder Urothelial Carcinoma (71.7%; 91 cases), 
Lung Squamous Cell Carcinoma (70.8%; 126 cases), Skin 
Cutaneous Melanoma (65.5%; 182 cases) and Stomach 
Adenocarcinoma (60.3%; 173 cases). Supplementary 
Table 1 and Supplementary File 1 summarises the 
frequency of overall alterations (copy number alterations 
plus mutations) in all cancer studies analysed. 
The majority of autophagy gene alterations were 
copy number amplifications and - at a lower frequency - 
copy number deletions and mutations in autophagy genes. 
In contrast, in Prostate Adenocarcinoma a large number of 
copy number deletions were found, mainly in the ATG5 
and ZBTB24 gene (Supplementary File 1). 
Interestingly, some cancers show very low copy 
number alterations. For example, alterations in autophagy 
genes were much less common in Thyroid Carcinoma 
(7.5%) and Glioblastoma (2.2%) than in other cancer 
types. Precise control of autophagy in these types of 
cancer may provide a benefit to tumour growth and may 
expose vulnerabilities for anti-cancer strategies. 
Neuro-endocrine Prostate Cancer displayed an 
interesting profile, showing gene alterations in 61.7% of 
cases, with many overlapping amplifications (Figure 2). 
For example, some cases have copy number amplifications 
in as many as 34 out of 47 autophagy genes. This 
remarkable up-regulation of autophagy copy numbers 
deserves further investigation as it can be expected that 
the autophagy pathway is highly dysfunctional in this type 
of cancer. 
Next, we analyzed individual autophagy gene 
amplifications present in the studied cancer types 
(Supplementary File 1 and Supplementary Table 2). We 
selected all cancer types where data is based on more 
than 100 cases and where more than 50% autophagy gene 
alterations were detected in the cumulative study. Overall, 
when looking at single gene alterations, the incidence 
was relatively low across all 47 genes. Most individual 
genes are altered at a frequency of less than 10% and there 
is no single gene that stands out as a candidate tumour 
driver across multiple cancer types. Instead, individual 
cancer types show an increased frequency in selected 
genes. For instance, in Prostate Adenocarcinoma, frequent 
copy number deletion for ZBTB24 (13%) and for ATG5 
(12%) was observed. A markedly high number of copy 
number deletions were also observed for the PIK3C3 
gene in Pancreatic cancer (24%), whereas copy number 
amplifications for ATG9B (17%), ATG4B (16%) and 
MAP1LC3C (13%) were commonly found. MAP1LC3C 
was also frequently amplified in Breast Cancer (14%) and 
Ovarian Serous Cystadenocarcinoma (10%). Overall, the 
LC3 family of proteins together account for 44.8% of 
gene amplifications in Breast cancer patient xenografts 
and 35.5% of amplifications in Neuroendocrine Prostate 
Cancer (Figure 3), suggesting an important role for 
this gene family in cancer. Most single gene alterations 
were non-overlapping in the same samples, with 
exception of Neuroendocrine Prostate Cancer which 
showed remarkable overlap of multiple autophagy gene 
amplifications in the same samples. 
Autophagy gene mutations in cancer
In addition to copy number alterations, the 
frequency of gene sequence mutations is an important 
feature to assess the role of autophagy genes in cancer. 
Thus, we investigated the frequency of gene mutations in 
the 47 selected autophagy genes. 
We were particularly interested to identify 
genes demonstrating hotspot mutations, which may be 
indicative of a causal link between cancer development 
Table 1: Hotspot mutations in human autophagy genes in cancer samples. 
Gene Mutation Cancer Type Functional consequence
ATG16L1
T300A
R399*/L/P
A582V/E
Diffuse Large B-Cell Lymphoma
Multiple
Multiple
Reduced stability/loss
Missense/nonsense
Missense
ATG5 K235/236fs Stomach Adenocarcinoma FS deletion
MAP1LC3A R70H Stomach/Pancreas Missense
PIK3C3 V856G Invasive Breast Carcinoma Missense
RB1CC1 L1171/1172fs Stomach/SCLC FS insertion/deletion
ULK1 R137H Multiple Missense
ULK2 K178fs Stomach Adenocarcinoma FS deletion
ULK4 K593fs Multiple FS insertion/deletion
UVRAG S237fs Multiple FS deletion
VCP N616fs Multiple FS insertion/deletion
Abbreviations: fs – frameshift, SCLC – small cell lung cancer.
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Figure 2: Frequency of autophagy gene expression changes in Neuroendocrine Prostate Cancer. Gene alterations for the 47 
selected autophagy genes were investigated for copy number amplifications, deletions and mutations in the cBio portal cancer sequencing 
database. Red colour indicates copy number amplifications and blue colour indicates deletions. 
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and gene function. Overall, we found ten genes with 
potential hotspot mutations at one specific site (Figure 
4): ATG16L1 (4 cases, T300A), ATG5 (5 cases K235/236 
frameshift), MAP1LC3A (4 cases, R70C/H), PIK3C3 
(6 cases, V856G), RB1CC1 (7 cases, L1171/1172 
frameshift), ULK1 (4 cases, R137H), ULK2 (4 cases, 
K178 frameshift), ULK4 (20 cases, K593 frameshift), 
UVRAG (6 cases, S237 frameshift) and VCP (9 cases 
N616 frameshift). The functional consequence of most of 
these mutations result in a deficient protein, for instance by 
premature termination as a consequence of frameshifting 
(Table 1). However, for some genes the consequence of 
mutation is less clear and may result in functional protein. 
The T300A mutation for ATG16L1 has been previously 
reported as a risk allele for Crohn’s disease [18]. The 
T300A mutation renders the protein more susceptible 
to caspase-mediated cleavage, thus resulting in reduced 
stability [19, 20] and intracellular pathogen clearance [21]. 
It is interesting to note that the same mutation occurs in 
some cancer samples and so reduced activity of ATG16L1 
may have functional consequences in other diseases as 
well as Crohn’s disease. 
Another gene mutation with potential functional 
consequence is the MAP1LC3A R70H substitution. 
Previously, a functional role for residue R68 and 
surrounding residues in MAP1LC3A has been proposed 
[22]. Thus, mutation of this residue may result in a change 
of conformation that can affect the function of LC3 and 
result in reduced autophagic flux. The arginine-rich motif 
R68-R70 is highly conserved in other LC3 members 
including MAP1LC3B and MAP1LC3C (Figure 5A). 
We next explored whether mutations in this region in 
MAP1LC3 family members were more commonly found 
in other cancer databases as well. Overall, we found 3 
R69H and 6 R70C/H mutations in MAP1LC3A and 4 
R76C/H mutations in MAP1LC3C in the cBio, ICGC and 
COSMIC databases (Table 2). 
Slower processing of MAP1LC3A R70H 
compared to wild-type MAP1LC3A
All LC3 family members undergo multiple 
processing steps to convert a pro-LC3 form into the 
autophagosome-associated LC3-II form that bears a lipid 
anchor at the C-terminus. This proteolytic processing is 
mediated by autophagy proteases of the ATG4 family 
member via an intermediate LC3-I form that has a 
C-terminal truncation at G120 and sub-sequent addition 
of a lipid anchor by ATG3/7. In order to investigate 
whether the R70H mutation results in altered MAP1LC3A 
cleavage, we tested ATG4B-mediated processing of 
MAP1LC3A using an in vitro cleavage assay. Briefly, 
MAP1LC3A tagged with GST at the C-terminus was co-
incubated with recombinant ATG4B and cleavage activity 
was determined by quantification of the cleaved bands 
visualized on a protein gel over time (Supplementary File 
2). Overall, MAP1LC3A R70H displayed a slower kinetic 
for ATG4B-mediated cleavage (Figure 5B), pointing to a 
functional role of the R70 residue in this context. In silico 
modeling of the R70H substitution using a crystal structure 
of MAP1LC3A (PDB:3WAL) shows a conformational 
Table 2: Mutations within the arginine-rich stretch (R68-70) in MAP1LC3A and corresponding sequence in 
MAP1LC3C. 
Gene Mutation Cancer Type sample ID Database
hMAP1LC3A R69H Cervix Carcinoma TCGA-DR-A0ZM COSMIC [COSM459773]and cBio Portal
R69H Pancreas 8066440 COSMIC [COSM459773]
R69H Pancreas DO49141 ICGC [PACA-AU]
R70C Upper Aerodigestive tract HN_62854 COSMIC (COSM124308]and cBio Portal
R70H Stomach DO38567 ICGC [STAD-US]
R70H Stomach DO48032 ICGC [STAD-US]
R70H Stomach TCGA-BR-8361 cBio Portal
R70H Stomach TCGA-CG-4306 cBio Portal
R70H Pancreas TCGA-IB-7651 cBio Portal
hMAP1LC3C R76C Endometrium TCGA-AX-A0J1 COSMIC [COSM906534]and cBio Portal
R76C Large Intestine TCGA-AZ-6598 COSMIC [COSM906534]
R76H Kidney TCGA-BP-5202 COSMIC [COSM1492022]
R76R Stomach DO10276 ICGC [COAD-US]
R76H Melanoma MEL-JWCI-WGS-34 cBio Portal
Only separate sample donors identified in the three databases COSMIC, ICGC and cBio Portal are shown for the respective 
mutations. Overall, 14 somatic mutations in the triple arginine-stretch of MAP1LC3A and the corresponding sequence in 
MAP1LC3C were found.
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change that leads to re-arrangement and co-ordination 
of the imidazole ring of R70H adjacent to residue D48 
(Figure 5C). Overall, the substitution of R70 by a histidine 
may result in a structural conformation change that is less 
favourable for cleavage. 
In order to investigate the cleavage of MAP1LC3A 
and the R70H mutant in cells, we generated a cell-
based LC3A cleavage reporter assay based on the 
luciferase release assay that was previously described 
for MAP1LC3B2 [23]. This reporter is based on release 
of Gaussia luciferase from an Actin-LC3 tether into 
supernatants by unconventional secretion [24]. The 
amount of luciferase released into supernatants correlates 
with ATG4B-mediated cleavage of the reporter. First, 
we tested the functionality of the Actin-MAP1LC3A-
dNGLUC reporter by assessing the response to ATG4B 
overexpression. As shown in Figure 5D, basal levels 
of luciferase release were similar for the LC3B2 and 
LC3A reporter (20.7% and 21.2%, respectively). Upon 
transfection of ATG4B, 57.2% and 57.4% of total 
luciferase activity was found in supernatants for LC3B2 
and LC3A, respectively. These results demonstrate that the 
Actin-LC3A-dNGLUC reporter is functional and LC3A 
is a cleavable substrate for ATG4B. Next, we compared 
the release of luciferase for MAP1LC3A and MAP1LC3A 
R70H. Basal levels of release were significantly reduced 
for the R70H mutant, displaying only 12.9% of total 
luciferase activity in supernatants when compared to 
wild-type LC3A with 21.2% of total luciferase activity 
in supernatants (Figure 5E). These results confirm the in 
vitro cleavage data demonstrating that LC3A R70H has 
a slower processing when compared to wild-type LC3A. 
In order to confirm a reduced capacity for LC3A 
processing in cells, we transfected Flag-tagged LC3A and 
LC3A R70H mutant in HEK293 cells and investigated the 
abundance of LC3A-I and LC3A-II forms by western-
blotting. The major form in untreated cells is LC3A-I 
(upper band in the blot shown in Figure 6A) with two lower 
bands that correspond to lipidated LC3-II. We noticed that 
LC3A R70H is expressed at significantly lower levels than 
LC3A, but shows the same pattern with higher levels of 
LC3A-I over LC3A-II (Figure 6A). Upon treatment with 
Bafilomycin A, the levels of LC3A-II increased for LC3A 
but not for LC3A R70H, suggesting that autophagic flux 
is reduced for the R70H mutant (Figure 6A). This effect is 
even more pronounced for LC3AG120 and LC3AG120 R70H, 
C-terminal truncations that by-passes pro-LC3A cleavage. 
When cells are expressing LC3AG120 R70H, the levels of 
LC3A R70H-II were significantly reduced when compared 
to the WT LC3AG120-II, indicating that the majority of the 
R70H isoform is not lipidated (Figure 6A). In summary, 
these results indicate that processing of LC3A R70H is 
reduced compared to WT LC3A, both in vitro and in vivo. 
Finally, we were interested to see if reduced 
processing of LC3A R70H manifests as a reduction in 
LC3A-positive autophagosomes. We therefore expressed 
GFP-LC3A and GFP-LC3A R70H in HEK293 cells 
and monitored GFP-positive puncta by fluorescence 
microscopy (Figure 6B). Generally, we observed a lower 
number of LC3A-positive puncta than LC3B-puncta. 
Upon treatment with Torin, a compound that enhances 
autophagy, the number of both LC3A- and LC3B-positive 
puncta increases, an effect that can be further enhanced by 
co-treatment of cells with Torin and Bafilomycin A (Figure 
6B). In contrast, cells expressing GFP-LC3A R70H did 
not show any appearance of LC3A R70H-positive puncta 
even when cells were treated with Torin plus Bafilomycin 
A. These results indicate that LC3A R70H does not 
partition into autophagosomal puncta, most likely due to 
a processing defect. 
DIscUssION
The importance of autophagy in tumour initiation 
and maintenance has been recognized but efforts to 
Figure 3: Frequency of LC3 family member gene expression changes in various cancer types. The cumulative gene 
expression changes for 4 LC3 family members are shown (MAP1LC3A, MAP1LC3B, MAP1LC3B2, MAP1LC3C). Shown in blue colour 
are copy number deletions, in red are copy number amplifications and in green are mutations.
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Figure 4: Mutations in selected autophagy genes in various cancer types. A, The position of frequent gene mutations identified 
in the cBioportal cancer database for ten autophagy genes are shown. Green colour indicates missense mutations and red colour indicates 
nonsense or splice mutations. 
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Figure 5: Reduced processing of LC3A R70H in vitro. A., sequence alignment of human MAP1LC3A, MAP1LC3B and 
MAP1LC3C. Alignment was done using ClustalW. B., ATG4B-mediated cleavage of MAP1LC3A R70H-GST is slower than cleavage of 
MAP1LC3A wild-type. Recombinant MAP1LC3A-GST and MAP1LC3A R70H-GST were incubated with ATG4B for 20 min at 37 °C and 
resolved by polyacryalamide gel electrophoresis. The bands for uncleaved and cleaved MAP1LC3A-GST were quantified using IMAGEJ 
and normalized to uncleaved MAP1LC3A-GST at time 0. C., Structure of MAP1LC3A (PDB: 3WAL). R68 and R70 are highlighted in 
green. Amino acid side chains of Asp48, Arg68, Arg70 and mutated R70H are shown as sticks in green and red. Salt bridges are shown 
in dashed blue lines. The Figure was generated using PyMOL. D., LC3A processing in response to ATG4B. The Actin-LC3B2-dNGLUC 
and Actin-LC3A-dNGLUC luciferase release reporter were co-transfected with GFP as control or ATG4B in HEK293 cells by lipofection. 
Supernatants were harvested 48h thereafter and cells were lysed in lysis buffer. The total amount of luciferase was calculated in supernatants 
and cell lysates. Released luciferase as a percentage of total luciferase is an indicator of processing of both LC3 homologues. E., Luciferase 
release of Actin-LC3A R70H-dNGLUC is reduced compared to wild-type Actin-LC3A-dNGLUC. The fraction of released luciferase was 
calculated as in Figure 5D. 
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identify inhibitors of autophagy core proteins for anti-
cancer strategies have failed so far [25]. In addition, 
therapeutic development has been hampered by the 
complexity and contextual contradictory of autophagy, 
especially in the context of cancer [26]. The prevailing 
view is that autophagy may present a barrier in the initial 
Figure 6: Reduced LC3A R70H processing in cells. A. Flag-tagged LC3A and LC3A R70H were transfected in HEK293T cells and 
left untreated or treated with Bafilomycin A. Cell lysates were resolved by SDS-PAGE and analysed by western-blotting using anti-Flag 
antibodies. The R70H mutant displays a reduction in LC3A-II that does not accumulate upon treatment with Bafilomycin A1. Vinculin 
was used as loading control. NT - not transfected; CTRL - transfected with empty control vector. B., 293T cells were transfected with 
GFP-tagged LC3B, LC3A and LC3A R70H and subsequently treated with Torin 1 (250nM) or Torin1 plus Bafilomycin A and compared to 
DMSO treated cells. Cells were counter-stained with Hoechst 33342 to identify nuclei. 
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stages of transformation, thus supporting the function as a 
tumour suppressor, whereas once this barrier is overcome, 
autophagy may benefit continued tumour growth at 
later stages [4]. Our results reflect a static snapshot of 
autophagy gene expression in various cancers and do 
not take into account the developmental or dynamic 
nature of individual cancer types. However, this analysis 
provides important findings underscoring the relevance of 
autophagy genes in cancer biology.
In this study, we have explored two areas: firstly, 
we analysed autophagy gene alterations and mutations in 
various cancer types as extracted from publicly available 
data sets, and secondly, we interrogated whether individual 
autophagy gene products are significantly altered in 
various cancers. We have taken an unbiased and systematic 
approach to gain an overview of gene expression patterns 
of autophagy genes in a wide variety of human tumour 
samples. Overall, we observed that autophagy gene 
amplifications were more commonly observed than 
gene deletions in most cancer types. In contrast, in other 
tumour types such as thyroid cancer and glioblastoma, 
autophagy gene alterations were not present even though 
the datasets consisted of large numbers. As a consequence, 
these cancer types may be particularly vulnerable to 
alterations or mutations in autophagy genes as literature 
supports. There has been good evidence that these cancer 
patients may therapeutically benefit from enhancing 
autophagy by treatment with rapamycin or temozolomide 
[27, 28]. In addition, sensitizing glioblastoma cells by 
inhibition of autophagy by RNAi renders them more 
sensitive to apoptosis inducing compounds [29]. These 
findings underscore that glioblastoma offers particular 
vulnerabilities for therapeutic targeting in the autophagy 
pathway.
Alternatively, specific cancer driver mutations may 
exhibit a linkage to specific sets of altered autophagy genes 
in the context of cancer progression. This aspect was not 
addressed in our study, and accordingly, we cannot make 
any prediction whether alterations in any of the autophagy 
genes are causal to specific cancer development and 
progression. Also, the contribution of individual autophagy 
gene expression needs to be addressed experimentally, e.g. 
by systematic knockout, knock-in or genome editing of 
each autophagy gene or combinations across a variety of 
in vitro and in vivo models.
Another study recently reported cross-cancer 
profiling on a larger set of genes, including signaling 
molecules or potential interaction partners of the core 
proteins, using data available from The Cancer Genome 
Atlas (TCGA) [30]. A total of 211 genes was analysed 
in 11 cancer types, including invasive breast carcinoma, 
glioblastoma multiforme, acute myeloid leukemia and 
ovarian cystadenocarcinoma. A very low frequency of 
mutations in individual autophagy core genes in these 
cancer types was reported, which is in agreement with our 
study. The authors suggested that the autophagy machinery 
may be protected from alterations in some human cancers, 
supporting the notion that autophagy may be essential for 
progression of some tumour types. We largely agree with 
this assessment, and hypothesize that drug targeting of the 
autophagy core machinery may expose vulnerabilities for 
anti-cancer strategies. 
In this study we found a common mutation hotspot 
in four autophagy proteins occurring at a higher than 
average frequency in various cancers. One of them, 
MAP1LC3A is a member of the LC3 family of proteins 
and a key structural component of the autophagosome 
that undergoes processing by members of the ATG4 
family, most notably ATG4B. LC3 is first proteolytically 
cleaved to generate a C-terminal truncation, LC3-I that 
is then conjugated to phosphatidyl-ethanolamine to 
generate LC3-II. In the later stages of autophagy, LC3-II 
is de-conjugated by ATG4 to recycle LC3-I. The kinetics 
of LC3 processing is generally viewed as an indicator 
of autophagy flux. The identified MAP1LC3A R70C/H 
mutation substitutes a critical residue in MAP1LC3A 
that is required for LC3A processing. In the absence of 
ATG4, R70 and D48 form salt bridges (Figure 5C) while 
the side chain of R68 points to the interface of the protein. 
In complex with ATG4B, the salt bridges between R70 
and D48 break down and R68 forms new salt bridges 
with D171 of ATG4B (see crystal structure PDB:2Z0E). 
On LC3 binding, the regulatory loop and the N-terminal 
tail of ATG4B undergo large conformational changes. The 
open conformation could be stabilized by the interaction 
with non-substrate LC3, specifically forming salt bridges 
between R70 of LC3A and D9 of ATG4B, and favour 
membrane targeting of ATG4B that is required for LC3-
PE de-conjugation [31]. Thus, mutations in the arginine-
rich stretch of LC3 result in structural re-arrangements 
that can account for decreased processing by ATG4 
family members. This is underscored by findings that the 
surrounding residue R68 is deleted in a non-functional 
splice isoform of MAP1LC3A [22]. R68 is involved in 
binding of ATG4B and a R68A mutant has been shown 
to result in reduced cleavage by ATG4B [31]. This 
region has been implicated in cardiolipin binding and 
elimination of damaged mitochondria by mitophagy [32]. 
Overall, mutations in this stretch of residues R68, R69, 
R70 account for 9 cases of MAP1LC3A mutations and 
R76 mutations for 5 cases of MAP1LC3C in cancer. We 
suggest that slower processing of LC3A can result in a 
reduced autophagic flux and reduced availability of LC3-I 
for responses to cellular stress or damage. An alternative 
hypothesis is that R70 contributes to the binding of 
LIR domain proteins that then affect autophagosome 
maturation. For instance, it has recently been observed 
that FYCO-1, a protein required for autophagosome 
transport along microtubules [33] binds directly via its 
LIR domain to a region in LC3A and LC3B that includes 
R70, thereby affecting autophagosome maturation under 
basal conditions [34]. The precise mechanisms how a 
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R70H substitution contributes to defective autophagosome 
maturation will need to be studied in further detail. 
Recently, a distinct role for LC3A in cancer cell 
lines has been described [35]. The authors demonstrate 
that LC3A-positive autophagosomes are distinct from 
LC3B-positive autophagosomes and cell- or tissue-
specific roles for LC3A as opposed to LC3B may exist. 
LC3A has been identified as a biomarker in multiple 
cancer types including colorectal adenocarcinoma [36], 
non-small cell lung carcinoma [37], cutaneous malignant 
melanomas [38] and breast carcinoma [39]. Furthermore, 
it has been proposed that LC3A is frequently inactivated 
in human cancers [40], thus corroborating our observation 
that reports a defective LC3A variant in human cancer 
samples. 
The conclusions based on the reported analysis may 
be crucial for designing therapeutic strategies based on the 
use of autophagy inhibitors and activators and will have 
implications for the development of autophagy modulators 
as anti-cancer therapeutic agents. In particular, the role 
of defective LC3A processing in cancer warrants further 
investigation and a more detailed study into the role of 
LC3 family members in autophagosome formation and 
maturation in cells and tissues. 
MAtErIALs AND MEtHODs
Cancer gene expression database
The cBIO Cancer Genomics Portal (http://
cbioportal.org/) is an open access resource for cancer 
genomics data sets [41] and contains data from 69 cancer 
genomics studies with a total number of 17,177 samples. A 
table with references, the number of available samples per 
cancer study and data type can be found in Supplementary 
Table 1. 47 autophagy genes were selected for analysis 
on the basis that their primary function was involved 
in autophagy regulation rather than other processes. 
For this reason, signaling genes such as mTOR or AKT 
were excluded as (1) they are involved in general signal 
transduction and (2) they are highly relevant for cancer 
initiation, progression and maintenance and thus would 
skew the analysis. 
Plasmid cloning
cDNA encoding human ATG4B full length was 
obtained from pEAK-ATG4B [42] by digestion with EcoRI 
and NotI restriction enzymes and inserted into bacterial 
expression vector pGEX6P-1 (GE Healthcare, 27-4597-
01) in frame with GST-tag at the N-terminal creating 
pGEXATG4B. cDNA encoding MAP1LC3A was obtained 
by PCR from the ORFeome library (ThermoFisher) as 
templates and using primers LC3A_NcoI and LC3A_R 
(Supplementary File 1 and inserted to pET21-SmaI-
GST in frame at NcoI and SmaI restriction sites creating 
pETLC3A-GST. pET21-SmaI-GST was constructed by 
digestion of pET21d (Novagen, 69743-3) with BamHI and 
restriction digest with HindIII. SmaI-GST was obtained 
by PCR using pGEX6P-1 as template and primers SmaI-
GST and GST_HIndIII_R. The DNA was phosphorylated 
and digested with HindIII and inserted into pET21. 
pETLC3A70H-GST (for mutation of LC3A R70 to H70) 
was created by PCR using pETLC3A-GST as a template 
and primers LC3AR70H_F and LC3AR70H_R. All PCR 
were done at 30 cycles using Pyrobest DNA polymerase 
(Takara, R005A). Triple (3x) flag-LC3A, -LC3A R70H, 
-LC3AG120 and -LC3AG120 R70H were generated by sub-
cloning the fragments (originally cloned into pDONR233) 
into a 3x flag-N terminus destination vector using the 
Gateway Recombination System (Invitrogen), according 
to the manufacturer’s protocol. Plasmids were verified by 
sanger sequencing.
The luciferase release reporter Actin-LC3A-
dNGLUC and Actin-LC3A R70H-dNGLUC were 
generated by replacing LC3B2 sequence in the original 
luciferase release reporter [42] with the corresponding 
LC3A sequence. MAP1LC3A-dNGLUC and MAP1LC3A 
R70H-dNGLUC were synthesized by Genscript and 
inserted into pEAK12-Actin-LC3B2-dNGLUC by 
restriction cloning using EcoRI and NotI. pEAK12-GFP-
LC3A and pEAK12-GFP-LC3A R70H were generated by 
removing dNGLUC from the constructs described above, 
using NheI and NotI, followed by 30 minute incubation 
with Klenow large fragment DNA Polymerase (NEB). 
Cell culture and transfection
293T cells were grown in Dulbecco’s modified 
Eagle’s medium containing 10% fetal bovine serum, 
sodium pyruvate and penicillin/streptomycin. Cells were 
seeded at the density of 1x105 cells/well (12 well plate) 
or 7.5x103 cells/well (96 well plate) and transfected 
on the following day with 1ug or 250 ng of plasmid, 
respectively, for 48 hours, using X-tremeGENE (Roche) 
or Lipofectamine 2000 (Invitrogen) and according to 
the manufacturer’s protocol. Before harvesting, medium 
was replaced and cells were treated for 2 hours with 
Bafilomycin A1 (10 nM). 
Expression and purification
Expression plasmids pGEXATG4B, pETLC3A-
GST and pETLC3A70H-GST were transformed into E. 
coli BL21 (DE3)-R3-lambda-PPase obtained from the 
Structural Genomics Consortium, Oxford University. 
Protein inductions and purifications were conducted as 
described before for CLK2cd [43]. GST-ATG4B were 
digested with PreScission Protease (GE Healthcare, 27-
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0843-01) and stored at 6 mg/ml at -80 °C in 50 mM Tris-
HCl, pH 8.0, 150 mM NaCl, 0.5 mM EDTA, 0.1 mM 
EGTA, 33% glycerol and 1 mM DTT.
In vitro ATG4B proteolysis assay
The assay was done at 37 °C in a reaction volume of 
20 µl containing 0.00133 µg/µl of ATG4B and 0.525 µg/µl 
of LC3A-GST or LC3A70H-GST in buffer A containing 
150 mM NaCl, 50 mM Tris-HCl pH 8.0 and 2 mM DTT. 
The reaction was stopped by addition of the same volume 
of 2X SDS sample buffer and boiling for 5 min. The 
samples were analysed on a 4-20% Mini-PROTEAN® 
TGX™ Precast Gel (Bio-Rad, 456-1096) and Coomassie 
Brilliant Blue Staining. Percentage of the substrate that 
remain at each reaction time point was equal to OD
LC3-GST
/
(OD
LC3-GST 
+ ODGST + ODLC3-I) × 100%.
Luciferase release assay
HEK293 cells were transfected using Lipofectamine 
2000 according to the manufacturer’s instructions. 48 h 
after transfection of Actin-LC3B2-dNGLUC, Actin-
LC3A-dNGLUC and Actin-LC3A R70H-dNGLUC in 
the presence or absence of ATG4B or GFP as control, 
supernatants were harvested and cells were lysed in 
lysis buffer (50 mM Tris HCl, pH 7.5, 150 mM NaCl, 
1% NP-40 and protease inhibitors). Luciferase activity 
was measured using native coelenterazine (Cambridge 
Bioscience) in Gaussia luciferase analysis buffer [24]. 
In order to account for different transfection efficiencies, 
the amount of released luciferase as a percentage of total 
luciferase in both supernatant and lysate was calculated. 
Western-blotting
Cells were collected, washed with 1 ml PBS and 
resuspended in 100 µl of cold lysis buffer containing. 
Lysate was cleared by centrifugation at 14,000 rpm for 
15 minutes. 10 µg of lysate was mixed with 5x sample 
buffer and boiled for 5 minutes. The proteins were 
resolved by SDS-PAGE (4-20%) and transferred to a 
PVDF membrane. After blocking with 5% milk PBS/
tween for 1 h, the membrane was probed with an anti-
Flag antibody (M2, Sigma) or anti-Vinculin (ab18058, 
Abcam) and then washed and exposed to anti-secondary 
immunofluorescence antibodies (Li-cor Biosciences). 
Detection was performed on the Odyssey Imaging System 
(Li-cor Biosciences). 
Fluorescence microscopy and image acquisition
293T cells were transfected with GFP-tagged 
versions of LC3B, LC3A and LC3A R70H and treated 
with Torin 1 or Torin 1 plus Bafilomycin A1 for 2h. Cells 
were then fixed with 4% paraformaldehyde for 15 minutes, 
washed three times with PBS and stained with Hoechst 
33342 (1:10.000). Images were acquired using the Opera 
High Content Screening System (Perkin Elmer) with a 40x 
objective in at least 6 replicates per condition. Nuclei were 
identified on the 365nm channel and GFP-LC3 spots on 
the 488nm channel  the Opera High Content Screening 
System (Perkin Elmer), using the 488nm and 365nm lasers 
and objective lens 40X.
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